Eindhoven-based health tech startup Salvia BioElectronics has raised €53 million in a Series B round to accelerate the clinical and commercial rollout of its migraine treatment technology.
The round was led by Innovation Industries, with Invest-NL and the EIC Fund joining in, alongside returning investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM, and Thuja Capital.
The company is pioneering a neuromodulation therapy known as MySalvia Therapy, which offers a personalized, minimally invasive treatment option for chronic migraine sufferers.
Addressing an urgent medical need
Chronic migraine affects millions globally and costs the EU and US an estimated $110 billion annually. Existing treatments often fall short, with most patients discontinuing medication within a year. Salvia BioElectronics’s approach offers a promising alternative, especially for patients who’ve exhausted other options.
Founded in 2017 by Hubert Martens, Salvia BioElectronics’s implant technology targets specific nerves associated with migraines using ultra-thin implants and wearable activation devices. The therapy allows patients to self-administer stimulation as needed, offering more control and potential long-term relief.
Advertisement
Paving the way for FDA and EU approval
The fresh capital will fund Salvia’s ongoing RECLAIM study, a double-blind, sham-controlled trial across Europe and Australia. It will also support efforts to obtain FDA approval in the US and additional regulatory clearances in Europe and Australia ahead of a commercial launch.
A step toward a new category of migraine care
Innovation Industries partner Caaj Greebe called Salvia’s platform a “life-changing solution” for a historically underserved group. Meanwhile, founder Martens emphasized the company’s mission: “Migraine is not ‘just a headache.’ It’s a neurological condition that robs people of their lives. We want to help them reclaim it.”
With its patient-centric design, scalable platform, and global regulatory ambitions, Salvia BioElectronics is poised to redefine how chronic migraine—and possibly cluster headaches—are treated.
